Stuttgart - Delayed Quote EUR

Adaptive Biotechnologies Corporation (1HM.SG)

3.8790

+0.2290

+(6.27%)

As of July 23 at 10:00:00 PM GMT+2. Market Open.

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

30 scientific abstracts will be presented using clonoSEQ for MRD assessment across multiple types of blood cancersSEATTLE, May 30, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment wi

GlobeNewswire 7 days ago

ADPT
Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Goldman Sachs 46th Annual Global Healthcare Conference in Miami, FL. Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Wednesday, June 11th at 5:40 a.

GlobeNewswire 8 days ago

ADPT
Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57

A week ago, Adaptive Biotechnologies Corporation ( NASDAQ:ADPT ) came out with a strong set of first-quarter numbers...

Simply Wall St. last month

ADPT
Adaptive Biotechnologies First Quarter 2025 Earnings: Beats Expectations

Adaptive Biotechnologies ( NASDAQ:ADPT ) First Quarter 2025 Results Key Financial Results Revenue: US$52.4m (up 25...

Simply Wall St. last month

ADPT
Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

SEATTLE, May 01, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the quarter ended March 31, 2025. “We had a strong start to 2025 with 34% MRD revenue growth, driven by continued acceleration in clonoSEQ test volume and disciplined execution,”

GlobeNewswire last month

ADPT
Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

SEATTLE, April 10, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 1, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern T

GlobeNewswire last month

ADPT
Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

clonoSEQ is now covered to monitor for recurrence in MCL patients who are in treatment-free remissionSEATTLE, April 08, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses diagnostic technologies through its Molecular Dia

GlobeNewswire last month

ADPT
Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD assay available for clinical use and covered by Medicare SEATTLE, March 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that it has launched an

GlobeNewswire 2 months ago

ADPT
Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank

Scotiabank analyst Sung Ji Nam raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $12 from $10 and keeps an Outperform rating on the shares. The company ended FY24 on a “strong note,” beating expectations across the board, the analyst tells investors. The firm continues to think there is significant growth potential ahead for the company’s minimal residual disease business. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try

TipRanks 3 months ago

ADPT
Adaptive Biotechnologies Full Year 2024 Earnings: EPS Beats Expectations

Adaptive Biotechnologies ( NASDAQ:ADPT ) Full Year 2024 Results Key Financial Results Revenue: US$179.0m (up 5.1% from...

Simply Wall St. 3 months ago

ADPT
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

SEATTLE, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today reported financial results for the fourth quarter and full year ended December 31, 2024. “2024 was a year of strong execution, marked by key catalysts achieved in our MRD business and advancements in our Immu

GlobeNewswire 3 months ago

ADPT
Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

SEATTLE, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the following investor conferences. BTIG 12th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference in Snowbird, UTParticipating on Wednesday, Februa

GlobeNewswire 3 months ago

ADPT
The 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99%

The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better...

Simply Wall St. 4 months ago

ADPT
Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

SEATTLE, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Tuesday, February 11, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time /

GlobeNewswire 4 months ago

ADPT
Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Pairing Adaptive Biotechnologies’ clonoSEQ MRD results with NeoGenomics’ COMPASS and CHART assessment services empowers clinicians and patients with meaningful insights across the treatment continuumSEATTLE and FORT MYERS, Fla., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, and NeoGenomics, Inc. (N

GlobeNewswire 4 months ago

ADPT

NEO
Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

SEATTLE, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today that the new Medicare Clinical Laboratory Fee Schedule (CLFS) rate for its next-generation sequencing (NGS)-based clonoSEQ® test for minimal – or measurable – residual disease (MRD) assessment is now in effect as of January 1,

GlobeNewswire 4 months ago

ADPT
Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SEATTLE, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA. Adaptive Biotechnologies’ management is scheduled to present on Tuesday, January 14th at 5:15 p.m. Pacific Time / 8:15

GlobeNewswire 4 months ago

ADPT
Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of treatment responses SEATTLE, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced new data

GlobeNewswire 5 months ago

ADPT
Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

SEATTLE, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced that its next-generation sequencing (NGS)-based clonoSEQ® test for measurable residual disease (MRD) assessment will be included in more than 65 abstracts across eight different types of blood cancer at the 66th Annual Meeting of the

GlobeNewswire 5 months ago

ADPT
Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations

Adaptive Biotechnologies ( NASDAQ:ADPT ) Third Quarter 2024 Results Key Financial Results Revenue: US$46.4m (up 23...

Simply Wall St. 6 months ago

ADPT

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Adaptive Biotechnologies Corporation (1HM.SG)

Adaptive Biotechnologies Highlights New Data at 2025 ASCO Annual Meeting and EHA 2025 Congress Demonstrating How clonoSEQ® MRD Assessment is Optimizing Patient Care and Drug Development in Lymphoid Cancers

Adaptive Biotechnologies to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.57

Adaptive Biotechnologies First Quarter 2025 Earnings: Beats Expectations

Adaptive Biotechnologies Reports First Quarter 2025 Financial Results

Adaptive Biotechnologies to Report First Quarter 2025 Financial Results on May 1, 2025

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Surveillance in Mantle Cell Lymphoma

Adaptive Biotechnologies Launches Assay Enhancements to Increase clonoSEQ® Sensitivity for Clinical MRD Detection in Diffuse Large B-Cell Lymphoma

Adaptive Biotechnologies price target raised to $12 from $10 at Scotiabank

Adaptive Biotechnologies Full Year 2024 Earnings: EPS Beats Expectations

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results

Adaptive Biotechnologies to Participate in Upcoming Investor Conferences

The 5.4% return this week takes Adaptive Biotechnologies' (NASDAQ:ADPT) shareholders one-year gains to 99%

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 11, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Adaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

Adaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual Meeting

Adaptive Biotechnologies Third Quarter 2024 Earnings: Beats Expectations